GovWire

Guidance: Shingles vaccine (Zostavax®): patient group direction (PGD) template

Public Health England

April 7
12:51 2021

Shingles vaccine (Zostavax) PGD template

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email publications@phe.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template is to support the administration of shingles (herpes zoster, live) vaccine in accordance with the national shingles (herpes zoster) immunisation programme.

It is valid from 1 April 2021 to 31 March 2023.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy or procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Published 14 July 2015
Last updated 7 April 2021 +show all updates
  1. Updated date in footer.

  2. Added version 09.00 - see page 2 for change history.

  3. Added version V08.00 - updated as routine review prior to PGD expiry (see document change history).

  4. Revised document to correct inclusion criteria date from 2013 to 2012 and add DOB note.

  5. Updated patient group direction template to allow vaccination from turn of age 70 or 78

  6. Updated patient group direction template valid up to 31 August 2017

  7. Updated PGD to allow for intramuscular administration (in line with the amended product license).

  8. Updated the shingles PGD to include detailed information on the use of the shingles vaccine in immunosuppressed individuals.

  9. First published.

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: